← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Dipeptidyl peptidase 4 (DPP-4) inhibitors
alogliptin
A10BH04
Forms & Strengths
- Oral tablets: 6.25 mg
- Oral tablets: 12.5 mg
- Oral tablets: 25 mg
Adult Dosing
- Type 2 diabetes mellitus: 25 mg orally once daily
- Renal impairment (eGFR 30 to <60 mL/min/1.73m2): 12.5 mg orally once daily
- Renal impairment (eGFR <30 mL/min/1.73m2): 6.25 mg orally once daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients <18 years of age
Indications
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Mechanism of Action
- Dipeptidyl peptidase-4 (DPP-4) inhibitor
- Slows inactivation of incretin hormones GLP-1 and GIP
- Increases insulin synthesis and release in a glucose-dependent manner
- Decreases glucagon secretion and hepatic glucose production
Contraindications
- History of a serious hypersensitivity reaction to alogliptin, such as anaphylaxis, angioedema, or severe cutaneous adverse reactions
Adverse Reactions
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Hypoglycemia (when used with insulin or secretagogues)
- Acute pancreatitis
- Severe joint pain (arthralgia)
- Hepatic failure and elevated liver enzymes
- Hypersensitivity reactions (anaphylaxis, angioedema, urticaria)
Drug Interactions
- Insulin and insulin secretagogues (sulfonylureas): increased risk of hypoglycemia, dose reduction of insulin or secretagogue may be required
Curated Content: Needs Vetting Before Put to Clinical Use